Q-omics provides the consensus-scored RAB5C profile across patient tissues and cancer cell-line models. RAB5C expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, RAB5C is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RAB5C protein abundance shows 20,439 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight COAD, HNSC, and PDAC as cancer lineages where RAB5C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB5C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB5C survival associations across molecular data types. RAB5C RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB5C RNA expression–survival associations across cancer types. High RAB5C expression shows unfavorable associations in MESO, LIHC, ACC and UVM, but favorable associations in COAD and SCLC. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for RAB5C RNA expression.
This table summarizes RAB5C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RAB5C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB5C shows lower tumor expression in KICH and KIRC and higher tumor expression in HNSC, LIHC, BRCA and CHOL. The HNSC box plot shows higher RAB5C RNA expression in tumor versus normal tissue (log2 FC = +0.886, t-test p < 0.001).
This table shows molecular features associated with RAB5C in patient tissues and cancer cell lines. In patient samples, RAB5C shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB5C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
